American Sexual Offender Castration Treatment and Legislation

International Perspectives on the Assessment and Treatment of Sexual Offenders: Theory, Practice, and Research

Volumn , Issue , 2011, Pages 543-571

  Del Busto, Elena ^a   Harlow, Michael C ^b  

^a BRYN MAWR HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

"Dynamic psychiatry"; American sexual offender castration treatment and legislation; Cytoproterone acetate (CPA); Ethical considerations; Evolution of american legislative policy; History of chemical castration; National incident based reporting system (NIBRS); Treatment of the sex offender

Indexed keywords

EID: 84885789390     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119990420.ch29     Document Type: Chapter

References (104)

1. Abel, G. (1989). Paraphilias. In Kaplan & Sadock (Eds.), Comprehensive textbook of psychiatry (Vol. 1, pp. 1069-1085). Baltimore, MD: Williams and Wilkins.
2. Abel, G., Becker, J., & Cunningham-Rathner, J. (1984). Complications, consent, and cognitions in sex between children and adults. International Journal of Law and Psychiatry, 7, 89-103.
3. Abel, G., & Harlow, N. (2002). Stop child molestation book. Philadelphia: Xlibris.
4. Abel, G., & Osborne, C. (1992). The paraphilias: The extent and nature of sexually deviant and criminal behavior. Clinical Forensic Psychiatry, 15, 675-687.
5. Agnew, J. (2001). An overview of paraphilia. Verereology: The Interdisciplinary International Journal of Sexual Health, 14, 148-156.
6. AMA (1998). Court initiated medical treatments in criminal cases (No. CEJA Report 4-A-98), Chicago, IL: American Medical Association.
7. APA (2000). Diagnositic and Statistical Manual of Mental Disorders (DSM-IV TR) (4th ed.). Washington, DC: American Psychiatric Association.
8. Atkinson, R. (1993). Introduction to psychology. Fort Worth, TX: Thompson.
9. Avari, K., & Bhiwgade, D. (1992). Effect of depot medroxyprogesterone acetate and testosterone ananthate on the testis of albino rats: ultrastructural and biochemical studies. Indian Journal of Experimental Biology, 30, 1118-1127.
10. Barbaree, H., Langton, C.,&Peacock, E. (2006). The factor structure of static actuarial items: its relation to prediction. Sexual Abuse:AJournal of Research and Treatment, 18, 207-226.
11. Bartosh, D., Garby, T., Lewis, D., & Gray, S. (2003). Differences in the predictive validity of actuarial risk assessments in relation to sex offender type. International Journal of Offender Therapy and Comparative Criminology, 47, 422-438.
12. Becker, J., & Murphy, W. (1998). What we know and do not know about assessing and treating sex offenders. Psychology, Public Policy and Law, 4, 116-137.
13. Beier, K. (1998). Differential typology and prognosis for dissexual behavior-a follow-up study of previously expert-appraised child molesters. International Journal of Legal Medicine, 111, 133-141.
14. Berlin, F., & Meinecke, C. (1981). Treatment of sex offenders with antiandrogenic medication: conceptualization, review of treatment modalities and preliminary findings. The American Journal of Psychiatry, 138, 601-607.
15. Blacher, R. (1995). Historical perspective of the "sex psychopath" statute: From the revolutionary era to the present Federal crime bill. Mercer Law Review, 46, 889-920.
16. Blanchard, R., & Barbaree, H. (2005). The strength of sexual arousal as a function of the age of the sex offender: comparisons among pedophiles, hebephiles, and teleiophiles. Sexual Abuse: A Journal of Research and Treatment, 17, 441-456.
17. Blanchard, R., Barbaree, H., Bogaert, A., Dickey, R., Klassen, P., Kuban, M., et al. (2000). Fraternal birth order and sexual orientation in pedophiles. Archives of Sexual Behavior, 29, 463-478.
18. Blanchard, R., Watson, M., Choy, A., Dickey, R., Klassen, P., Kuban, M., et al. (1999). Pedophiles: mental retardation, maternal age, and sexual orientation. Archives of Sexual Behavior, 28, 111-127.
19. Bogaerts, S., Daalder, A., Vanheule, S., Desmet, M., & Leeuw, F. (2008). Personality disorders in a sample of paraphilic and nonparaphilic child molesters: A comparative study. International Journal of Offender Therapy and Comparative Criminology, 52, 21-30.
20. Bradford, J. (1983). The hormonal treatment of sexual offenders. The Bulletin of the American Academy of Psychiatry and the Law, 11, 159-169.
21. Bradford, J. (1995). Pharmacological treatment of the paraphilias (Vol. 14). Washington, DC: American Psychiatric Press.
22. Bradford, J. (2000). The treatment of sexual deviation using a pharmacological approach. Journal of Sex Research, 37, 248-257.
23. Bradford, J. (2001). The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behavior. The Canadian Journal of Psychiatry, 46, 26-33.
24. Bradford, J., & Pawlak, A. (1993). Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Archives of Sexual Behavior, 22, 383-402.
25. Briken, P., Hill, A., & Berner, W. (2003). Pharmacotherapy of Paraphilias with Long-Acting Agonists of Luteinizing Hormone-Release Hormone: A Systematic Review. Journal of Clinical Psychiatry, 64, 890-897.
26. California Welfare and Institutions Code (2002) Para. 6604. Sacremento, CA.
27. Chandy, J., Blum, R., & Resnick, M. (1996). Gender-specific outcomes for sexually abused adolescents. Child Abuse and Neglect, 20, 1219-1231.
28. Chow, E.,&Choy, A. (2002). Clinical characteristics and treatment response to SSRI in a female pedophile. Archives of Sexual Behavior, 31, 211-215.
29. Cohen, L., & Galynker, I. (2002). Clinical features of pedophilia and implications for treatment. Journal of Psychiatric Practice, 8, 276-289.
30. Cohen, L., Nikiforov, K., Gans, S., Poznansky, O., McGeoch, P., Weaver, C., et al. (2002). Heterosexual male perpetrators of childhood sexual abuse: a preliminary neuropsychiatric model. Psychiatric Quarterly, 73, 313-336.
31. Cooper, A., Sandhu, S., Losztyn, S., & Cernovsky, Z. (1992). A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. The Canadian Journal of Psychiatry, 37, 687-693.
32. Craissati, J. (2004). Managing high risk sex offenders in the community: A psychological approach. New York: Routledge.
33. Curnoe, S., & Langevin, R. (2002). Personality and deviant sexual fantasies: an examination of the MMPIs of sex offenders. Journal of Clinical Psychology, 58, 803-815.
34. Davis, T. (1974). Cyproterone acetate for male hypersexuality. Journal of International Medical Research, 2, 159-163.
35. de Voogt, H., Smith, P., Pavone-Macaluso, M., de Pauw, M., & Suciu, S. (1986). Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. The Journal of Urology, 135, 303-307.
36. Dickey, R., Nussbaum, D., Chevolleau, K.,&Davidson, H. (2002). Age as a differential characteristic of rapists, pedophiles, and sexual sadists. Journal of Sex and Marital Therapy, 28, 211-218.
37. Donovan, B. (1985). Hormones and human behavior (Vol. viii). Cambridge, UK: Cambridge University Press.
38. Doren, D. (2002). Diagnositc issues within sex offender civil commitment assessments: Defining relevant paraphilias. In N. Hale & M. H. Seawell (Eds.), Evaluating sex offenders: A manual for civil commitments and beyond. Thousand Oaks, CA: Sage.
39. DSM-IV. (2000). Diagnositic and Statistical Manual of Mental Disorders (DSM-IV TR) ( 4th ed.). Washington, DC: American Psychiatric Association.
40. Edward, N. (1952). Norwalk State Hospital, May 22, California.
41. FDA (2004). Black Box Warning Added Concerning Long Term Use of Depo-Provera Contraceptive Injection. FDA Talking Paper, November 17, retrieved http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166395.pdf.
42. Finkelhor, D. (1994). Answers to Important Questions about the Scope and Nature of Child Sexual Abuse [Electronic Version]. Future of Children, 4.
43. Firestone, P., Bradford, J., McCoy, M., Greenberg, D., Curry, S.,&Larose, M. (2000). Prediction of recidivism in extrafamilial child molesters based on court-related assessments. Sexual Abuse: A Journal of Research and Treatment, 12, 203-221
44. Gawande, A. (1997). The unkindest cut: The science and ethics of castration. Retrieved from http://www.slate.com/id/2660/.
45. Grasswick, L., & Bradford, J. (2002). Osteoporosis associated with the treatment of paraphilias: A clinical review of seven case reports. Forensische Psychiatrie und Psychotherapie, 9(Suppl), 40.
46. Greenberg, D., Bradford, J., & Curry, S. (1995). Infantophilia-a new subcategory of pedophilia?: Apreliminary study. The Bulletin of the American Academy of Psychiatry and the Law, 23, 63-71.
47. Greenberg, D., Da Silva, J.,&Loh, N. (2002). Evaluation of the Western Austrialian sex offender treatment unit (1987-1999):Aquantitative analysis. Perth: The University of Western Australia.
48. Grossman, L., Martis, B.,&Fichtner, C. (1999). Are sex offenders treatable? A research overview. Psychiatric Services, 50, 349-361.
49. Hacker, F., & Frym, M. (1955). The sexual psychopath act in practice: A critical discussion. The California Law Review, 43, 766.
50. Hales, R., & Yudofsky, S. (2008). Sexual and gender identity disorders. In Clinical Textbook of Psychiatry ( 5th ed., pp. 729-753). Washington DC: APA.
51. Hall, R. (2007). A profile of pedophilia: Definition, characteristics of offenders, recidivism, treatment outcomes, and forensic issues. Mayo Clinic Proceedings, 82, 457-471.
52. Hanson, R. (2001). Age and sexual recidivism:Acomparison of rapists and child molesters (No. 2001-01). Ottawa: Department of the Solicitor General of Canada.
53. Hanson, R., & Bussiere, M. (1998). Predicting relapse: A meta-analysis of sexual offender recidivism studies. Journal of Consulting and Clinical Psychology, 66, 348-362.
54. Hanson, R., & Morton-Bourgon, K. (2005). The characteristics of persistent sexual offenders: A meta-analysis of recidivism studies. Journal of Consulting and Clinical Psychology, 73, 1154-1163.
55. Harris, A.,&Hanson, R. (2004). Sex offender recidivism:Asimple question. (Report No. 2004-03) Ottawa: Public Safety and Preparedness Canada.
56. Harrison, K. (2008). The castration cure? Prison Service Journal, 175, 13-18.
57. Hill, A., Briken, P., Kraus, C., Strohm, K., & Berner, W. (2003). Differential pharmacological treatment of paraphilias and sex offenders. International Journal of Offender Therapy and Comparative Criminology, 47, 407-421.
58. Hoffet, H. (1968). On the use of the testosterone blocking agent cyproterone acetate (SH 714) in hospitalized sex offenders and psychiatric patients. (Preliminary report). Praxis, 57, 221-230.
59. Huggins, C.,&Hodges, C. (1941). Studies on prostatic cancer, I: The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research, 1, 293-297.
60. Johnson, C. (2002). Child maltreatment 2002: Recognition, reporting and risk. Pediatrics International, 44, 554-560.
61. Lanning, K. (2001). Child Molesters: A Behavioral Analysis (No. Grant No. 2007-MCCX-K001). Alexandria: National Center for Missing and Exploited Children.
62. Lieberman, D. (1972). Commitment of mentally disordered sex offenders to state hospitals. In S. Pollack (Ed.), The sex offender and the law (pp. 131-132). Los Angeles: University of Southern California.
63. Maletzky, B., & Field, G. (2003). The Biological treatment of dangerous sexual offenders. A review and preliminary report of the Oregon pilot Depo-Provera program. Aggression and Violent Behavior, 8, 391-392.
64. Maletzky, B., & Steinhauser, C. (2002). A 25-year follow-up of cognitive/behavioral therapy with 7,275 sexual offenders. Behavior Modification, 26, 123-147.
65. McEvoy, G. (Ed.). (1999). AHFS drug information. Bethesda: American Society of Health System Pharmacists.
66. Meyer, W., 3rd, Cole, C.,&Emory, E. (1992).Depo Provera treatment for sex offending behavior: An evaluation of outcome. The Bulletin of the American Academy of Psychiatry and the Law, 20, 249-259.
67. Money, J. (1987). Treatment guidelines: Antiandrogen and counseling of paraphilic sex offenders. Journal of Sex and Marital Therapy, 13, 219-223.
68. Morsi, A., Jamal, S., & Silverberg, J. (1996). Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clinical Endocrinology, 44, 121-124.
69. Murray, J. (2000). Psychological profile of pedophiles and child molesters. The Journal of Psychology, 134, 211-224.
70. Olver, M.,&Wong, S. (2006). Psychopathy, sexual deviance, and recidivism among sex offenders. Sexual Abuse: A Journal of Research and Treatment, 18, 65-82.
71. Parys, B., Hamid, S., & Thomson, R. (1991). Severe hepatocellular dysfunction following cyproterone acetate therapy. British Journal of Urology, 67, 132-134.
72. Petrunik, M. (2002). Managing unacceptable risk: Sex offenders, community response, and social policy in the United States and Canada. International Journal of Offender Therapy and Comparative Criminology, 46, 483-511.
73. Pierce, E. (1995). Angina pectoris and myocardial infarction with the use of leuprolide acetate. American Journal of Obstetrics and Gynecology, 172, 1323.
74. Prevention, N. I. o. J. C. f. D. C. a. (1998). Prevalence, Incidence and Consequences of Violence Against Women Survey. Retrieved from http://www.ncjrs.gov/pdffiles/172837.pdf.
75. Psychiatry, G. f. t. A. o. (1977). Psychiatry and sex psychopath legislation: The 30s to the 80s. New York: Group for the Advancement of Psychiatry.
76. Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Jr., Forciea, M.,&Owens, D. (2008). Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 148, 680-684.
77. Raymond, N., Coleman, E., Ohlerking, F., Christenson, G., & Miner, M. (1999). Psychiatric comorbidity in pedophilic sex offenders. The American Journal of Psychiatry, 156, 786-788.
78. Reilly, D., Delva, N., & Hudson, R. (2000). Protocols for the use of Cyproterone, Medroxyprogesterone and Leuprolide in the treatment of paraphilia. The Canadian Journal of Psychiatry, 45, 559-563.
79. Roila, F., Crino, L., Carloni, G., & Natalini, G. (1993). Cyproterone acetate: Hepatotoxicity and prostatic cancer treatment. Annals of Oncology, 4, 701.
80. Rosler, A., & Witztum, E. (1998). Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. The New England Journal of Medicine, 338, 416-422.
81. Rosler, A., & Witztum, E. (2000). Pharmacotherapy of paraphilias in the next millennium. Behavioral Sciences and the Law, 18, 43-56.
82. Saleh, F., & Guidry, L. (2003). Psychosocial and biological treatment considerations for the paraphilic and nonparaphilic sex offender. Journal of the American Academy of Psychiatry and the Law, 31, 486-493.
83. Santen, R. (1995). The testis. In P. Felig, J. Baxter&L. Frohman (Eds.), Endocrinology and metabolism (3rd ed., pp. 885-972). New York: McGraw-Hill.
84. Santen, R., & Bardin, C. (1973). Episodic lutenizing hormone secretion in man: pulse analysis, clinical interpretation, physiologic mechanism. The Journal of Clinical Investigation, 52, 2617-2628.
85. Schober, J., Byrne, P.,&Kuhn, P. (2006). Leuprolide acetate is a familiar drug that may modify sex-offender behaviour: the urologist's role. British Journal of Urology International, 97, 684-686.
86. Schober, J., Kuhn, P., Kovacs, P., Earle, J., Byrne, P., & Fries, R. (2005). Leuprolide acetate suppresses pedophilic urges and arousability. Archives of Sexual Behavior, 34, 691-705.
87. Scott, C., & del Busto, E. (2009). Chemical and surgical castration. In R. Wright (Ed.), Sex offender laws: Failed policies, new directions (pp. 392), New York: Springer.
88. Scott, C., & Gerbasi, J. (2003). Sex offender registration and community notification challenges: the Supreme Court continues its trend. Journal of the American Academy of Psychiatry and the Law, 31, 494-501.
89. Scott, C., & Holmberg, T. (2003). Castration of sex offenders: Prisoners' rights versus public safety. Journal of the American Academy of Psychiatry and the Law, 31, 502-509.
90. Seto, M., Harris, G., Rice, M.,&Barbaree, H. (2004). The screening scale for pedophilic interests predicts recidivism among adult sex offenders with child victims. Archives of Sexual Behavior, 33, 455-466.
91. Snyder, H. (2000). Sexual assault of young children as reported to law enforcement. Pittsburgh, PA: National Center for Juvenile Justice.
92. Sreenivasan, S., Weinberger, L., & Garrick, T. (2003). Expert testimony in sexually violent predator commitments: conceptualizing legal standards of "mental disorder" and "likely to reoffend." Journal of the American Academy of Psychiatry and the Law, 31, 471-485.
93. Stone, T., Winslade, W., & Klugman, C. (2000). Sex offenders, sentencing laws and pharmaceutical treatment: a prescription for failure. Behavioral Sciences and the Law, 18, 83-110.
94. Strum, S., McDermed, J., Scholz, M., Johnson, H., & Tisman, G. (1997). Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British Journal of Urology, 79, 933-941.
95. Sutherland, E. (1950). The sexual psychopath laws. Journal of Criminal Law and Crimonology, 40, 447-448.
96. Tjaden, P.,&Thoennes, N. (2000). Extent, nature, and consequences of intimate partner violence: Findings from the National Violence Against Women Survey. (Publication No.: NCJ 181867). Washington, DC: US Department of Justice.
97. Tjaden, P., & Thoennes, N. (2006). Extent, nature and consequences of rape victimization. Retrieved from http://www.ncjrs.gov/pdffiles1/nij/210346.pdf.
98. Tucker, D. (2008, October). Assessment and treatment of adult sex offenders. Paper presented at the Chemical and Surgical Castration: Ethics and Efficacy, Seattle, WA.
99. Vallis, K., & Waxman, J. (1988). Tumor flare in hormone therapy. In B. Stroll (Ed.), Endocrine management of cancer 2: Contemporary therapy (pp. 144-152). Basel, CH: Karger.
100. Vandiver, D. (2006). A prospective analysis of juvenile male sex offenders: characteristics and recidivism rates as adults. Journal of Interpersonal Violence, 21, 673-688.
101. Vandiver, D., & Kercher, G. (2004). Offender and victim characteristics of registered female sexual offenders in Texas: a proposed typology of female sexual offenders. Sexual Abuse: A Journal of Research and Treatment, 16, 121-137.
102. Wallace, I., Edwin, R.,& Gach, J. (Eds.). (2007). The history of psychiatry and medical psychology. New York: Springer-Verlag.
103. Weiss, P. (1999). Assessment and treatment of sex offenders in the Czech Republic and in Eastern Europe. Journal of Interpersonal Violence, 14, 411-421.
104. Zonana, H., Abel, G.,&Bradford, J. (1999). Dangerous sex offenders a task force report of the American Psychiatric Association. Washington, DC: APA.